These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1591 related items for PubMed ID: 25366685

  • 1. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM.
    J Clin Oncol; 2015 Jan 20; 33(3):244-50. PubMed ID: 25366685
    [Abstract] [Full Text] [Related]

  • 2. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A.
    Lancet Oncol; 2011 Sep 20; 12(9):852-61. PubMed ID: 21862407
    [Abstract] [Full Text] [Related]

  • 3. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.
    Oncotarget; 2017 Jul 18; 8(29):47154-47160. PubMed ID: 28454085
    [Abstract] [Full Text] [Related]

  • 4. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.
    Lancet Oncol; 2015 Jan 18; 16(1):87-97. PubMed ID: 25481791
    [Abstract] [Full Text] [Related]

  • 5. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.
    Lancet Oncol; 2016 Nov 18; 17(11):1579-1589. PubMed ID: 27617661
    [Abstract] [Full Text] [Related]

  • 6. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
    Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL.
    Ann Oncol; 2016 Jun 18; 27(6):1013-1019. PubMed ID: 26961146
    [Abstract] [Full Text] [Related]

  • 7. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
    Poveda AM, Davidson R, Blakeley C, Milner A.
    Future Oncol; 2019 Nov 18; 15(32):3651-3663. PubMed ID: 31553234
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
    Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Loman N, Robertson JD, Mann H, Kaufman B.
    Gynecol Oncol; 2016 Feb 18; 140(2):199-203. PubMed ID: 26723501
    [Abstract] [Full Text] [Related]

  • 9. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.
    Clin Cancer Res; 2017 Aug 01; 23(15):4086-4094. PubMed ID: 28223274
    [Abstract] [Full Text] [Related]

  • 10. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, Alexandre J, You B, Bastian S, Krebs MG, Wang D, Waqar SN, Lanasa M, Rhee J, Gao H, Rocher-Ros V, Jones EV, Gulati S, Coenen-Stass A, Kozarewa I, Lai Z, Angell HK, Opincar L, Herbolsheimer P, Kaufman B.
    Lancet Oncol; 2020 Sep 01; 21(9):1155-1164. PubMed ID: 32771088
    [Abstract] [Full Text] [Related]

  • 11. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
    Munroe M, Kolesar J.
    Am J Health Syst Pharm; 2016 Jul 15; 73(14):1037-41. PubMed ID: 27385701
    [Abstract] [Full Text] [Related]

  • 12. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.
    N Engl J Med; 2018 Dec 27; 379(26):2495-2505. PubMed ID: 30345884
    [Abstract] [Full Text] [Related]

  • 13. Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study.
    Kubo T, Muramatsu J, Arihara Y, Murota A, Ishikawa K, Yoshida M, Nagashima H, Tamura F, Ikeda Y, Usami M, Ono M, Nakamura H, Watanabe D, Shibata T, Kasahara K, Sakurai A, Takada K.
    Jpn J Clin Oncol; 2024 Jan 07; 54(1):47-53. PubMed ID: 37791389
    [Abstract] [Full Text] [Related]

  • 14. Olaparib shows promise in multiple tumor types.
    Cancer Discov; 2013 Jul 07; 3(7):OF5. PubMed ID: 23847380
    [Abstract] [Full Text] [Related]

  • 15. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
    Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U.
    N Engl J Med; 2012 Apr 12; 366(15):1382-92. PubMed ID: 22452356
    [Abstract] [Full Text] [Related]

  • 16. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A.
    Lancet; 2010 Jul 24; 376(9737):245-51. PubMed ID: 20609468
    [Abstract] [Full Text] [Related]

  • 17. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
    Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.
    J Natl Cancer Inst; 2014 Jun 24; 106(6):dju089. PubMed ID: 24842883
    [Abstract] [Full Text] [Related]

  • 18. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA.
    Ann Oncol; 2019 Apr 01; 30(4):551-557. PubMed ID: 30753272
    [Abstract] [Full Text] [Related]

  • 19. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
    Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J.
    Lancet; 2010 Jul 24; 376(9737):235-44. PubMed ID: 20609467
    [Abstract] [Full Text] [Related]

  • 20. Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China.
    Ni J, Cheng X, Zhou R, Xu X, Guo W, Chen X.
    J Ovarian Res; 2019 Nov 28; 12(1):117. PubMed ID: 31775908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 80.